IJDVL the success story!

As the Editor-in-Chief of IJDVL, it gives me great pleasure to announce that IJDVL has surpassed previous metrics records to score an impact factor of 3.2 in the recently released JCR by Clarivate Analytics, making it the top dermatology journal in the nation. Considering that the score is 3.1 without self-citations, the accomplishment feels even sweeter!

This demonstrates the journal’s depth and reach into all parts of the nation, where it is often read, accessed and cited. We are quite delighted that the journal received 197 citations and had a 10% increase in impact factor. In addition to having encouraging instant citation metrics, we anticipate that IJDVL will continue to set new standards in the future.

The JCR result is all the more significant because it is mirrored in the most recent Scopus CiteScore. The journal increased by 14% to reach a new high of 2.1! Fifty five per cent of papers that are published receive citations. In both SJR and JCR releases, IJDVL proudly ranks in the top quartile for its subject category. As Editor-in-Chief, I am grateful to all of my editors and reviewers for their unselfish efforts in making this possible. Above all, though, I want to express my gratitude to the journal’s writers for adding excellent clinical information.

IJDVL will continue to publish on diverse topics with the aim of educating the dermatology fraternity and bringing together the research work happening in the nooks and corners of the world to a common platform, so that we can all learn from each other and improvise our research and clinical endeavours. In this quest, we have continued to publish focussed as well as diversified topics.

In one of our recent chain of topics, we published the influence of Janus Kinase (JAK) Inhibitors in various dermatological conditions, highlighting their role in atopic dermatitis, psoriatic arthritis, psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis, graft-versus-host disease, etc.^1,2 Overseas authors have continued to show their interest in publishing with us and have enriched the journal with high-quality original investigation articles like the one addressing the use of photodynamic diagnosis with reflectance confocal microscopy, on tumour margin detection and surgical outcomes.³ We continued to show our interest in publishing molecular investigations addressing topics like cytokine cross-talks between TNF-α and IL-17 in nail psoriasis or reviews exploring the role of vitamin D on skin cancers and tumour microenvironment.^4,5 While doing so, we did not forget that our primary objective is to provide our young readers and budding clinicians with the ever-changing information on the subject. Therefore, we published several top-notch reviews addressing clinical topics like dermatological adverse effects of hair dye use, nail cosmetics, comparative efficacy and therapeutic positioning of biologics in hidradenitis suppurativa and aetiology, pathogenesis and management of neuropathic itch, etc.^6-9 In the same endeavour, we published a consensus on the prescribing practices of tranexamic acid in a commonly encountered condition in clinical practice, melasma.¹⁰

I would like to take this opportunity to further encourage the authors to continue submitting such high-quality articles to the journal and assist us in growing IJDVL and making it an even stronger journal in the worldwide competition, while adhering to our primary objective of providing our readers with high-quality clinical information and knowledge.

Long live IJDVL! And long live IADVL!

Archana Singal

Editor-in-Chief

Indian Journal of Dermatology, Venereology and Leprology